NASDAQ$OCUL
Ocular Therapeutix Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Ocular Therapeutix reported financial results for the first quarter of 2021 and provided updates on its ophthalmology pipeline.
Ocular Therapeutix's first quarter of 2021 saw significant progress, with DEXTENZA® revenue up over 200% year-over-year and a record 16,634 billable units sold. The company is advancing its pipeline, including Phase 2 programs in wet-AMD and glaucoma, and expects to complete a Phase 2 clinical trial in dry eye disease.
- DEXTENZA® achieved a quarterly record of 16,634 billable units sold to end customers, representing 15% sequential growth.
- DEXTENZA® revenue increased by approximately 220% compared to the first quarter of 2020.
- The company presented pre-clinical and clinical data at the 2021 ARVO meeting.
- A Phase 2 clinical trial evaluating OTX-DED for dry eye disease has dosed its first patient.
Headline financials
Revenue & EPS history
Ocular Therapeutix · Revenue · Quarterly
$7.34M
Revenue by segment
Ocular Therapeutix · $6.7M total across 1 segment · Q1 2021
- Product Revenue$6.7M+219.0%100.0%
Forward guidance
The Company believes that existing cash and cash equivalents, as of March 31, 2021, will enable the Company to fund planned operating expenses, debt service obligations and capital expenditure requirements through 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
-2.3%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+5.2%
Avg return
30 days after
33%
14 / 43 earnings
Positive
+24.0%
Q3 2016
Best reaction
-20.4%
Q3 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.7% | -1.2% | -10.0% | |
| Q3 2025 | -4.4% | -4.9% | +8.9% | |
| Q1 2025 | -12.4% | -19.8% | -4.8% | |
| Q4 2024 | +9.6% | +27.3% | +18.1% | |
| Q3 2024 | -13.6% | -15.8% | -18.0% | |
| Q2 2024 | +1.8% | +1.3% | +6.3% | |
| Q1 2024 | -0.9% | -2.4% | -10.3% | |
| Q4 2023 | -6.9% | -5.2% | -20.7% | |
| Q3 2023 | -10.7% | -23.7% | +34.8% | |
| Q2 2023 | -13.7% | -3.5% | -13.7% | |
| Q1 2023 | +4.8% | -0.6% | +18.6% | |
| Q4 2022 | -0.6% | -17.6% | -16.8% | |
| Q3 2022 | -9.7% | -6.6% | -20.0% | |
| Q2 2022 | -1.0% | +10.5% | +18.5% | |
| Q1 2022 | -4.3% | -5.5% | +12.4% | |
| Q4 2021 | -0.4% | -10.7% | -8.5% | |
| Q3 2021 | +9.5% | +0.0% | -2.9% | |
| Q2 2021 | +4.4% | +2.2% | +1.6% | |
| Q1 2021 | -5.1% | -9.4% | -13.3% | |
| Q4 2020 | +6.0% | -2.1% | -16.0% | |
| Q3 2020 | +6.6% | +11.1% | +68.8% | |
| Q2 2020 | +0.0% | -2.6% | -8.7% | |
| Q1 2020 | -1.7% | -4.8% | +9.0% | |
| Q4 2019 | -11.4% | +47.3% | +1.5% | |
| Q3 2019 | -5.5% | -4.4% | +38.2% | |
| Q2 2019 | -9.5% | -6.9% | -5.6% | |
| Q1 2019 | -4.6% | -1.6% | -9.0% | |
| Q4 2018 | -0.2% | +1.4% | +3.3% | |
| Q3 2018 | +8.0% | +1.0% | +11.1% | |
| Q2 2018 | +8.7% | +14.5% | +23.2% | |
| Q1 2018 | +0.3% | +6.4% | +7.7% | |
| Q4 2017 | -0.8% | +6.4% | +2.7% | |
| Q3 2017 | -13.7% | -12.1% | -34.4% | |
| Q2 2017 | -4.3% | -1.5% | +13.9% | |
| Q1 2017 | -11.3% | -9.9% | +20.9% | |
| Q4 2016 | -1.6% | +0.5% | -5.6% | |
| Q3 2016 | +24.0% | +42.9% | +77.3% | |
| Q2 2016 | -4.4% | +11.0% | +18.3% | |
| Q1 2016 | -8.0% | — | — | |
| Q4 2015 | +2.4% | — | — | |
| Q3 2015 | -20.4% | — | — | |
| Q2 2015 | -12.2% | — | — | |
| Q1 2015 | — | — | — | |
| Q3 2014 | +5.6% | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro